Bb2121 Induces 100% Response Rate in Multiple Myeloma – Targeted Oncology
Targeted Oncology |
Bb2121 Induces 100% Response Rate in Multiple Myeloma
Targeted Oncology According to findings from a small phase I study, all patients with multiple myeloma showed a response following treatment with an active dose of bb2121, an investigational anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell … |
